To evaluate the impact of hepatic steatosis on the outcome of treatment in patients with chronic hepatitis B infection treated with oral antiviral therapy. Materials and methods: The study was designed in Erciyes University Medical Faculty Department of Gastroenterology. Patients who received oral antiviral therapy because of chronic hepatitis B were included in the study. Liver biopsy specimens were re-evaluated and classified according to Brunt’s steatosis classification. Virological response to oral antiviral therapy was compared between patients with and without steatosis. Results: One hundred and nineteen patients were included in the study, of which 36.1% had hepatic steatosis. Virological response rates were 81% and 85.5% in patients with steatosis and without steatosis, respectively. There was no statistically significant difference in virological response rate between patients with and without steatosis (p: 0.78). Median hepatic fibrosis values were 3 and 2 in patients with steatosis and without steatosis respectively (p: 0.01). Conclusion: Many studies have researched the prevalence and effect of steatosis on the liver in chronic hepatitis B. Although steatosis does not affect the outcome of treatment, it is not a rare condition in chronic hepatitis B.
KARAMAN, AHMET; GÜRSOY, ŞEBNEM; SOYUER, IŞIN; KARAMAN, HATİCE; TORUN, MUHAMMET EDİP; YURCİ, MUSTAFA ALPER; BAŞKOL, MEVLÜT; GÜVEN, KADRİ; ÖZBAKIR, ÖMER; and YÜCESOY, MEHMET
"Effect of hepatic steatosis on virological response to nucleos(t)ide analogs therapy in patients with chronic hepatitis B,"
Turkish Journal of Medical Sciences: Vol. 43:
1, Article 13.
Available at: https://journals.tubitak.gov.tr/medical/vol43/iss1/13